4 - INTELLIGENT BIO SOLUTIONS INC. (0001725430) (Issuer)

4 - INTELLIGENT BIO SOLUTIONS INC. (0001725430) (Issuer)

SC 13G/A - INTELLIGENT BIO SOLUTIONS INC. (0001725430) (Subject)

SC 13G/A - INTELLIGENT BIO SOLUTIONS INC. (0001725430) (Subject)

SC 13G/A - INTELLIGENT BIO SOLUTIONS INC. (0001725430) (Subject)

SC 13G - INTELLIGENT BIO SOLUTIONS INC. (0001725430) (Subject)

SC 13G - INTELLIGENT BIO SOLUTIONS INC. (0001725430) (Subject)

SC 13G - INTELLIGENT BIO SOLUTIONS INC. (0001725430) (Subject)

SC 13D - INTELLIGENT BIO SOLUTIONS INC. (0001725430) (Subject)

SC 13G - INTELLIGENT BIO SOLUTIONS INC. (0001725430) (Subject)

8-K - INTELLIGENT BIO SOLUTIONS INC. (0001725430) (Filer)

10-Q - INTELLIGENT BIO SOLUTIONS INC. (0001725430) (Filer)

8-K - INTELLIGENT BIO SOLUTIONS INC. (0001725430) (Filer)

8-K - INTELLIGENT BIO SOLUTIONS INC. (0001725430) (Filer)

8-K - INTELLIGENT BIO SOLUTIONS INC. (0001725430) (Filer)

8-K - INTELLIGENT BIO SOLUTIONS INC. (0001725430) (Filer)

S-8 - INTELLIGENT BIO SOLUTIONS INC. (0001725430) (Filer)

8-K - INTELLIGENT BIO SOLUTIONS INC. (0001725430) (Filer)

8-K - INTELLIGENT BIO SOLUTIONS INC. (0001725430) (Filer)

8-K - INTELLIGENT BIO SOLUTIONS INC. (0001725430) (Filer)

The transaction further solidifies GBS' leadership in non-invasive, real-time diagnostic testing with an expanded portfolio and geographical reachGBS' global footprint includes operations in Australia, United Kingdom and the US NEW YORK, Oct. 04, 2022 (GLOBE NEWSWIRE) --  GBS Inc. (NASDAQ:GBS), a life sciences company developing non-invasive, real-time diagnostic testing for patients and their primary health practitioners at point of care, today announced it has acquired Intelligent Fingerprinting Limited (IFP), thus expanding the GBS platform of rapid, non-invasive diagnostic testing technologies. In addition, GBS announced it has begun the process of changing its corporate name. I

- Entered into exclusive agreement with Intelligent Fingerprinting Ltd. (IFP) for screening technology focused on drugs of abuse towards a prospective acquisition - - Completed collection and analysis in a study with coincidental sampling of oral fluid and blood to evaluate the time-course of glucose in oral fluids - - Company to host conference call & webcast today at 4:30 p.m. ET - NEW YORK, Aug. 31, 2022 (GLOBE NEWSWIRE) -- GBS Inc. (NASDAQ:GBS), a life sciences company developing non-invasive, real-time monitoring and diagnostic testing for patients and their primary health practitioners at point of care, today announced its preliminary financial results for the fourth financi

NEW YORK, Aug. 29, 2022 (GLOBE NEWSWIRE) -- GBS Inc. (NASDAQ:GBS), a life sciences company developing non-invasive, real-time diagnostic testing for patients and their primary health practitioners at point-of-care, today announced that it will release its financial results for the fourth quarter and full year ended June 30, 2022, shortly after the NASDAQ market close on Wednesday, August 31. Management will then host a conference call and webcast at 4:30 p.m. ET. Title:GBS Inc. Fourth Quarter and Full Year 2022 Financial Results Conference Call & WebcastDate:Wednesday, August 31, 2022Time:4:30 p.m. ETConference Call Details:Toll-Free: 877-407-3982International: 201-493-6780Conference ID: 1

The trial is single center, prospective study collecting coincident samples of oral fluids and blood to evaluate the time-course of glucose NEW YORK, July 13, 2022 (GLOBE NEWSWIRE) -- GBS Inc. (NASDAQ:GBS), a life sciences company developing non-invasive, real-time diagnostic testing for patients and their primary health practitioners at point-of-care, today announced completion of sample collection and analysis of glucose in oral fluid and blood samples from their clinical study at the Diabetes Research Institute of Sutter Health's Mills-Peninsula Medical Center (MPMC) in San Mateo, California. GBS will perform subsequent statistical analyses of the correlation of glucose levels amon

NEW YORK, June 23, 2022 (GLOBE NEWSWIRE) -- GBS Inc. (NASDAQ:GBS), a life sciences company developing non-invasive, real-time diagnostic testing for patients and their primary health practitioners at point-of-care, today announced that the Company and the University of Newcastle in Australia have selected a site for its proprietary biosensor technology. "Maintaining momentum with our partners at the University of Newcastle has been and will remain a principal objective to generating shareholder value and long-term success of the GBS technology," stated Dr. Steven Boyages, Interim Chief Executive Officer. "Our longstanding relationship with the University has matured over the years but as

NEW YORK, June 16, 2022 (GLOBE NEWSWIRE) -- GBS Inc. (NASDAQ:GBS), a life sciences company developing non-invasive, real-time diagnostic testing for patients and their primary health practitioners at point-of-care (the "Company"), today announced that the Company has adjourned its 2022 Annual Meeting of Stockholders (the "Annual Meeting") originally scheduled to be held on June 16, 2022, to July 13, 2022, at 4:00 p.m., Eastern Time, or at such other time or such other date to which the meeting may be adjourned. On June 16, 2022, the Company called to order its Annual Meeting. At the Annual Meeting, there were not present in person or by proxy at least a majority of the Company's common st

NEW YORK, June 16, 2022 (GLOBE NEWSWIRE) -- GBS Inc. (NASDAQ:GBS), a life sciences company developing non-invasive, real-time diagnostic testing for patients and their primary health practitioners at point of care, today announced that it has executed an exclusivity agreement with Intelligent Fingerprinting Limited ("IFP" or "Intelligent Fingerprinting") in respect of GBS's proposed acquisition of IFP (the "Exclusivity Agreement"). "By potentially combining Intelligent Fingerprinting's leadership position as a revolutionary point of care fingerprint sweat-based drug screening technology with our saliva-based glucose biosensor platform and manufacturing expertise, GBS would be able to serv

NEW YORK, May 16, 2022 (GLOBE NEWSWIRE) -- GBS Inc. (NASDAQ:GBS), a life sciences company developing non-invasive, real-time diagnostic testing for patients and their primary health practitioners at point-of-care, today announced that, today announced that Dr. Steven Boyages, GBS' interim CEO and Chairman of the Board, along with other management team members will participate at the H.C. Wainwright Global Investment Conference being held May 23–26, 2022 and invites investors to participate via virtual one-on-one meetings. Please see additional details below: H.C. Wainwright Global Investment Conference (Hybrid Conference)Date: Tuesday, May 24, 2022Time: 7:00 AM ETWebcast & Registration Li

NEW YORK, May 13, 2022 (GLOBE NEWSWIRE) -- GBS Inc. (NASDAQ:GBS), a life sciences company developing non-invasive, real-time diagnostic testing for patients and their primary health practitioners at point-of-care, today announced that, GBS's 2022 Annual Meeting of Shareholders will be held in a virtual-only meeting format via live audio webcast. The Company's proxy statement describing the formal business to be conducted at the meeting is available on the Investors section of the Company's website at: https://www.cstproxy.com/gbs/2022 Please see additional details below: Title:GBS, Inc. Virtual 2022 Annual Shareholder MeetingDate:Thursday, June 16, 2022Time:4:00 p.m. ET Toll-Free (US & Ca

- Initiated prospective study to collect coincident samples of oral fluid and blood following IRB approval - - Finalizing site selection at the University of Newcastle campus for the high-tech manufacturing and production facility - - $10.76 Million in Cash, Cash Equivalents, and Marketable Securities as of March 31, 2022, provides estimated runway into H1 2023 - -To host conference call and webcast today at 4:30 p.m. ET- NEW YORK, May 10, 2022 (GLOBE NEWSWIRE) -- GBS Inc. (NASDAQ:GBS), a life sciences company developing non-invasive, real-time diagnostic testing in the hands of patients and their primary health practitioners at point-of-care, today announced its financial results fo

Gainers Bionano Genomics (NASDAQ:BNGO) stock increased by 9.8% to $2.24. The company's market cap stands at $649.9 million. SAB Biotherapeutics (NASDAQ:SABS) stock moved upwards by 9.09% to $0.84. The market value of their outstanding shares is at $36.1 million. Kintara Therapeutics (NASDAQ:KTRA) stock increased by 9.06% to $0.11. The company's market cap stands at $8.7 million. Aytu BioPharma (NASDAQ:AYTU) shares increased by 8.38% to $0.22. The market value of their outstanding shares is at $13.7 million. BIMI Intl Medical (NASDAQ:BIMI) shares moved upwards by 7.74% to $0.33. The market value of their outstanding shares is at $12.4 million. Losers Eiger BioPharmaceuticals (NASD

The transaction further solidifies GBS' leadership in non-invasive, real-time diagnostic testing with an expanded portfolio and geographical reach   GBS' global footprint includes operations in Australia, United Kingdom and the US NEW YORK, Oct. 04, 2022 (GLOBE NEWSWIRE) --  GBS Inc. (NASDAQ:GBS), a life sciences company developing non-invasive, real-time diagnostic testing for patients and their primary health practitioners at point of care, today announced it has acquired Intelligent Fingerprinting Limited (IFP), thus expanding the GBS platform of rapid, non-invasive diagnostic testing technologies. In addition, GBS announced it has begun the process of changing its corporate name.

Gainers LogicBio Therapeutics (NASDAQ:LOGC) shares moved upwards by 641.3% to $2.02 during Monday's pre-market session. The company's market cap stands at $66.5 million. Myovant Sciences (NYSE:MYOV) stock moved upwards by 31.68% to $23.65. The company's market cap stands at $2.2 billion. Acorda Therapeutics (NASDAQ:ACOR) shares moved upwards by 20.36% to $0.36. The company's market cap stands at $8.7 million. NeuBase Therapeutics (NASDAQ:NBSE) shares moved upwards by 20.12% to $0.47. The company's market cap stands at $15.3 million. Zynerba Pharmaceuticals (NASDAQ:ZYNE) stock rose 19.79% to $0.88. The market value of their outstanding shares is at $40.1 million. GBS (NASDAQ:GBS) stoc

  Companies Reporting Before The Bell • Hywin Holdings (NASDAQ:HYW) is expected to report earnings for its fourth quarter. • Safe-T Gr (NASDAQ:SFET) is projected to report earnings for its second quarter. • Vera Bradley (NASDAQ:VRA) is likely to report earnings for its second quarter. • Brown Forman Inc Class B Common Stock (NYSE:BF) is expected to report quarterly earnings at $0.47 per share on revenue of $977.76 million. • Burning Rock Biotech (NASDAQ:BNR) is expected to report quarterly loss at $0.35 per share on revenue of $22.15 million. • VersaBank (NASDAQ:VBNK) is projected to report quarterly earnings at $0.21 per share on revenue of $19.29 million. • Chico's FAS (NYSE:CHS) i

GBS Inc. (NASDAQ:GBS), a life sciences company developing non-invasive, real-time diagnostic testing for patients and their primary health practitioners at point-of-care, today announced completion of sample collection and analysis of glucose in oral fluid and blood samples from their clinical study at the Diabetes Research Institute of Sutter Health's Mills-Peninsula Medical Center (MPMC) in San Mateo, California. GBS will perform subsequent statistical analyses of the correlation of glucose levels among these sample types. Daniel Brown, PhD, CCRC and Head of Clinical Affairs for GBS stated, "While a systematic literature review reveals numerous clinical investigations of salivary glucose

U.S. stocks traded lower this morning on Thursday. Investors, meanwhile, focused on some notable insider trades. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision. Below is a look at a few recent notable insider transactions for penny stocks. For more, check out Benzinga's insider transactions platform.3 GBS The Trade: GBS Inc. (NASDAQ:GBS) Chief Financial Officer Spiro Sakiris acquired a total of 15,970 shares at an average price of $0.61. To acquire these shares, it cost around $9.77 thousand.

By John Vandermosten, CFA NASDAQ:GBS READ THE FULL GBS RESEARCH REPORT GBS Signs Exclusivity Agreement for Fingerprint Drug Detection Company In a June 16th press release, GBS, Inc. (NASDAQ:GBS) announced that it had entered into an exclusivity agreement to acquire Intelligent Fingerprinting Limited (IFP), a UK-based device company that is developing a fingerprint reader for drug screening and detection. GBS management is now conducting due diligence on the private company that offers numerous synergies to GBS' legacy platform. Some of the primary synergies that can be shared between the two companies are: ➢ GBS' regulatory experience with FDA ➢ GBS' capital and cash balance ➢ G